Testosterone News and Research

Latest Testosterone News and Research

Fireside chat: BioSante's LibiGel and GVAX cancer vaccines portfolio

BioSante Pharmaceuticals, Inc. today announced that a BioSante presentation and corporate discussion are available at http://www.rodm.tv/video1269553400.

3 Apr 2010

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Healthy pre-and post-menopausal Japanese women who took a supplement of SE5-OH containing Natural S-equol, a novel soy germ-based ingredient under development for the management of menopausal symptoms, had measures of reproductive hormones that stayed within normal limits throughout the study.

3 Apr 2010

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

CPEX Pharmaceuticals Inc. today announced that its partner, Serenity Pharmaceuticals, has entered into a global agreement with Allergan, Inc. for the development and commercialization of Ser-120, a product candidate currently in Phase III clinical trials for the treatment of nocturia that utilizes CPEX's patented intranasal drug delivery technology.

2 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

Athletes and ethicists look at fairness in sport

Just in time for baseball’s opening day, a series of articles in the Hastings Center Report asks what constitutes fairness in elite sports and what it takes to stop cheating. New issues, including the prospect of gene doping and questions about which athletes are really “female,” are explored.

1 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

VIVUS terminates Luramist development, commercialization agreement with FemPharm

VIVUS, Inc. today announced that it has terminated the Development and Commercialization Agreement with FemPharm Pty Ltd. (a wholly owned subsidiary of Acrux Limited) for Luramist™, a metered dose transdermal application of testosterone for women.

1 Apr 2010

BioCision, Biohit announce co-promotion program

BioCision LLC today announced that it has agreed to a co-promotion program with Biohit Inc.. Biohit's ErgoTube microcentrifuge tubes will now be branded and sold by both Biohit Inc. and BioCision. In addition, Biohit Inc. will cross-promote BioCision's highly thermo-conductive CoolRack microfuge tube racks for use in combination with ErgoTubes.

31 Mar 2010

BioSante Pharmaceuticals completes Azur Pharma Elestrin royalty buydown

BioSante Pharmaceuticals, Inc. today announced the successful completion of the Azur Pharma Elestrin royalty buydown, and financial results for the year ended December 31, 2009.

31 Mar 2010

Study: Hormone replacement in joint fluid might be beneficial in treating osteoarthritis

German researchers determined that concentrations of the sex hormones, testosterone in men and estrogen in women, may have a positive effect on the regenerative potential of cartilage tissue. The study suggests hormone replacement in the joint fluid of men and women might be beneficial in treating late stages of human osteoarthritis by regenerating damaged tissue.

30 Mar 2010

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

New study may give men a way to combat high cholesterol without drugs

A new study from Iowa State University's Nutrition and Wellness Research Center may give men a way to combat high cholesterol without drugs -- if they don't mind sprinkling some flaxseed into their daily diet.

27 Mar 2010

Analgesics can decrease risk of breast or ovarian cancer

Postmenopausal women who regularly use aspirin and other analgesics (known as painkillers) have lower estrogen levels, which could contribute to a decreased risk of breast or ovarian cancer.

24 Mar 2010

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.

23 Mar 2010

Young men take riskier decisions in presence of attractive women, study confirms

The presence of an attractive woman elevates testosterone levels and physical risk taking in young men, according to a recent study in the inaugural issue of Social Psychological and Personality Science (published by SAGE).

20 Mar 2010

Early baldness may not be associated with risk of prostate cancer

Men who start losing their hair at an early age may be less likely to develop prostate cancer in the future, new research suggests.

18 Mar 2010

Low T Center opens new men's testosterone diagnosis and treatment center in Southlake, Texas

Low T Center announces the grand opening of its new men's testosterone diagnosis and treatment center located at 601 Zena Rucker Road, Suite 101 – the corner of Byron Nelson Parkway and FM 1709 in Southlake, Texas. This is the first and only low testosterone therapy clinic for men in the Metroplex.

18 Mar 2010

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.

18 Mar 2010

Lilly receives exclusive rights to commercialize Acrux's testosterone solution

Eli Lilly and Company and Acrux announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON™).

16 Mar 2010

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

BioSante Pharmaceuticals, Inc. today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer.

15 Mar 2010

Testosterone News and Research

Latest Testosterone News and Research

Fireside chat: BioSante's LibiGel and GVAX cancer vaccines portfolio

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

Athletes and ethicists look at fairness in sport

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

VIVUS terminates Luramist development, commercialization agreement with FemPharm

BioCision, Biohit announce co-promotion program

BioSante Pharmaceuticals completes Azur Pharma Elestrin royalty buydown

Study: Hormone replacement in joint fluid might be beneficial in treating osteoarthritis

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

New study may give men a way to combat high cholesterol without drugs

Analgesics can decrease risk of breast or ovarian cancer

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

Young men take riskier decisions in presence of attractive women, study confirms

Early baldness may not be associated with risk of prostate cancer

Low T Center opens new men's testosterone diagnosis and treatment center in Southlake, Texas

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

Lilly receives exclusive rights to commercialize Acrux's testosterone solution

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Testosterone News and Research

Latest Testosterone News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in